Alembic (APLLTD) Q2 FY27 Pharma's Profit Soars 82% as US Business Takes the Lead
Alembic Pharmaceuticals reported an 82% jump in Q2 profit, driven by a 77% surge in US formulations revenue and a sharp expansion in profitability.
Alembic Pharma's Q2 FY27 profit surged 81.8% to ₹334 crore, powered by a 36.3% revenue rise. The US formulations business grew 77%, leading a broad-based recovery and a significant margin expansion.
For Alembic Pharmaceuticals, the September quarter was a story of a long-awaited US-led acceleration finally arriving in full force. The company's profit more than doubled from the previous quarter, as a powerful mix of new launches and volume growth in its largest market drove both top-line expansion and a sharp improvement in profitability.
The numbers tell a clear story of acceleration. Revenue grew 36% year-on-year to ₹2,603 crore, while profit soared 82% to ₹334 crore. The real momentum is seen sequentially, with profit nearly doubling from Q1, and the net profit margin jumping 480 basis points to 12.8%. The quarter's performance lifted the trailing-twelve-month profit to ₹840 crore.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ2 FY27 | PreviousQ1 FY27 | Same quarter LYQ2 FY26 |
|---|---|---|---|
| Revenue (₹ Cr) | 2,603.0YoY +36% | 2,149.8 | 1,910.2 |
| Profit (₹ Cr) | 334.0YoY +82% | 172.4 | 183.7 |
| Net Profit Margin (%) | 12.8YoY +33% | 8.0 | 9.6 |
The US Engine Fires on All Cylinders
The standout driver was the US formulations business, which grew 77% year-on-year to ₹1,003 crore, according to reports from CNBC-TV18 and Business Today. This was fueled by new product launches and strong volume growth in the base portfolio. Management noted in an earnings call that the cancer drug bosutinib performed “far above expectations.” The underlying business, excluding new launches, still grew a healthy 23%.
This exceptional performance cascaded down the income statement. A favorable product mix helped gross margin expand 70 basis points to 73.7%, as per the AlphaStreet transcript. Operating leverage from higher volumes then flowed through, pushing the EBITDA margin to over 22%. This more than offset planned investments in the US branded business and higher freight costs.
Raising the Bar for the Full Year
Confidence from the strong first half prompted management to raise its full-year guidance. The company now expects consolidated revenue to grow 20-25% in FY27, up from the mid-teens range indicated earlier, as reported by Investing.com. The US generics business is projected to grow up to 40% this year.
The outlook for the next 18 months is supported by a pipeline of about 30 planned launches. A quarter of these are first-to-file or day-one opportunities, providing visibility beyond current exclusivity-led sales. The expanded partnership with DifGen Pharmaceuticals, providing access to over 20 complex generics, adds to this future runway.
The Costs and the Catch
The quarter was not without its pressures. Interest expense rose 57% year-on-year, partly linked to higher working capital needs for new US launches. CFO G. Krishnan noted on the call that working capital is tied to longer collection cycles for these launches, which should unwind over the coming quarters.
The market's reaction was unequivocally positive. The stock hit a 20% upper circuit on results day, closing nearly 13% higher, as reported by Business Standard. This surge reflects investor reward for both the growth beat and the upgraded guidance, placing the stock near the top of its 52-week range.
Key Points
- Alembic's Q2 profit surged 82% year-on-year, with the net profit margin expanding sharply to 12.8%.
- The US formulations business was the primary engine, growing 77% driven by new launches and strong volume.
- Management raised its FY27 consolidated revenue growth guidance to 20-25% from the mid-teens.
- The company has a pipeline of ~30 launches over the next 18 months to sustain momentum.
Hexa Perspective
The quarter marks a decisive shift from the margin pressure seen in Q1, demonstrating the operating leverage possible when the US business fires. The guidance upgrade signals management's confidence that this is more than a one-quarter spike. The key test will be sustaining growth as exclusivity periods for key products like bosutinib end in November. Success will hinge on the steady cadence of the broader launch pipeline and the continued ramp-up of the base portfolio. For now, the earnings trajectory has clearly inflected upward.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.
